Natalie Weiss
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Natalie Weiss has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Amy L. Rutt
Department of Otolaryngology‐Head and Neck Surgery Mayo Clinic Jacksonville Florida USA
8 shared publications - Eric Delgado Rendon
Florida State University College of Medicine Tallahassee Florida USA
2 shared publications Estephania Candelo
Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224
2 shared publicationsKaterina Green
Department of Otolaryngology - Head and Neck Surgery, Mayo Clinic, 4500 San Pablo, Rd S, Jacksonville, Florida 32224
2 shared publications- Nawfal Saleem
Lake Erie College of Osteopathic Medicine, 5000 Lakewood Ranch Blvd, Bradenton, Florida, 34211
2 shared publications Rockey Dahiya
Department of Otolaryngology - Head & Neck Surgery, Mayo Clinic , 4500 San Pablo Rd S, Jacksonville, FL 32224
2 shared publications
Latest Publications
- 19 September 2026
- Published by Elsevier in Journal of Voice
Therapy Dogs During In-Office Laryngologic Procedures: A Pilot Study
- 19 September 2026
- Published by Elsevier in Journal of Voice
Therapy Dogs During In-Office Laryngologic Procedures: A Pilot Study
- 18 August 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Symptom Burden and Sexual Quality of Life in Women With Idiopathic Subglottic Stenosis
Objective: To evaluate the connection between symptom burden and sexual quality of life in women with idiopathic subglottic stenosis (iSGS). iSGS is a rare fibroinflammatory disorder involving progressive airway narrowing and respiratory distress. While the impact on physical functioning is well‐established, the influence of iSGS on sexual health, a key component of quality of life, remains unexplored. Study Design: Anonymized cross‐sectional survey using validated questionnaires. Setting: Online international iSGS support group (Living with Idiopathic Subglottic Stenosis). Methods: The Dyspnea Index (DI), the Female Sexual Quality of Life (SQOL‐F) questionnaire, and the Medical Outcomes Health Survey (SF‐36) were distributed to an iSGS support group. Only complete responses were analyzed. Associations between DI and sexual quality of life were evaluated using correlation and linear regression. Median‐based symptom burden groupings were used for secondary descriptive comparisons. Results: 682 completed all items in the assigned questionnaires and met inclusion criteria. DI scores were inversely correlated with SQOL‐F (Rho = −0.305, P < .001). SQOL‐F was consistently lower among those with high symptom burden across nearly all items; only partner communication showed no difference. Each one‐point increase in DI predicted a 0.61‐point decrease in SQOL‐F ( B = −0.609, P < .001). High‐burden patients also reported significantly lower SF‐36 Physical (PCS) and Mental (MCS) Component Scores. Conclusions: Greater airway symptom burden in iSGS is associated with significantly diminished sexual and general health‐related quality of life. These findings reinforce a need for patient‐centered care that considers both physical and psychosocial well‐being.
- 18 August 2026
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Symptom Burden and Sexual Quality of Life in Women With Idiopathic Subglottic Stenosis
Objective: To evaluate the connection between symptom burden and sexual quality of life in women with idiopathic subglottic stenosis (iSGS). iSGS is a rare fibroinflammatory disorder involving progressive airway narrowing and respiratory distress. While the impact on physical functioning is well‐established, the influence of iSGS on sexual health, a key component of quality of life, remains unexplored. Study Design: Anonymized cross‐sectional survey using validated questionnaires. Setting: Online international iSGS support group (Living with Idiopathic Subglottic Stenosis). Methods: The Dyspnea Index (DI), the Female Sexual Quality of Life (SQOL‐F) questionnaire, and the Medical Outcomes Health Survey (SF‐36) were distributed to an iSGS support group. Only complete responses were analyzed. Associations between DI and sexual quality of life were evaluated using correlation and linear regression. Median‐based symptom burden groupings were used for secondary descriptive comparisons. Results: 682 completed all items in the assigned questionnaires and met inclusion criteria. DI scores were inversely correlated with SQOL‐F (Rho = −0.305, P < .001). SQOL‐F was consistently lower among those with high symptom burden across nearly all items; only partner communication showed no difference. Each one‐point increase in DI predicted a 0.61‐point decrease in SQOL‐F ( B = −0.609, P < .001). High‐burden patients also reported significantly lower SF‐36 Physical (PCS) and Mental (MCS) Component Scores. Conclusions: Greater airway symptom burden in iSGS is associated with significantly diminished sexual and general health‐related quality of life. These findings reinforce a need for patient‐centered care that considers both physical and psychosocial well‐being.
- Open Access
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Transnasal Application of Fibrin Glue for Orbital Lymphatic Malformation: A Case Report
Orbital lymphatic malformations (OLs) are rare vascular malformations that present major surgical challenges due to their friable, infiltrative nature, and proximity to vital structures. Endoscopic transnasal approaches provide unique access to the orbital apex and medial orbit, but the narrow working space can make dissection and bleeding control more difficult. Fibrin glue (FG) has rarely been used to solidify OL cystic spaces, decreasing the risk of bleeding and incomplete resection; this is the first report of its transnasal application. A mid-50s female with progressive OL causing severe proptosis and diplopia underwent combined transnasal and transconjunctival approach to lesion debulking. Intraoperatively, cyst contents along the uncinate process were aspirated and replaced with FG transnasally, enabling controlled removal without significant bleeding. Residual disease near the lower eyelid and orbital apex was managed postoperatively with sirolimus. The patient had rapid, sustained improvement in proptosis and diplopia, with imaging showing marked reduction in lesion volume and stable residual disease on follow-up. This first-reported transnasal application of FG emphasizes the expanding role of endoscopic surgeons in multidisciplinary orbital surgery and highlights FG as a versatile adjunct in challenging orbital pathology.
- 13 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessTransnasal Application of Fibrin Glue for Orbital Lymphatic Malformation: A Case Report
Orbital lymphatic malformations (OLs) are rare vascular malformations that present major surgical challenges due to their friable, infiltrative nature, and proximity to vital structures. Endoscopic transnasal approaches provide unique access to the orbital apex and medial orbit, but the narrow working space can make dissection and bleeding control more difficult. Fibrin glue (FG) has rarely been used to solidify OL cystic spaces, decreasing the risk of bleeding and incomplete resection; this is the first report of its transnasal application. A mid-50s female with progressive OL causing severe proptosis and diplopia underwent combined transnasal and transconjunctival approach to lesion debulking. Intraoperatively, cyst contents along the uncinate process were aspirated and replaced with FG transnasally, enabling controlled removal without significant bleeding. Residual disease near the lower eyelid and orbital apex was managed postoperatively with sirolimus. The patient had rapid, sustained improvement in proptosis and diplopia, with imaging showing marked reduction in lesion volume and stable residual disease on follow-up. This first-reported transnasal application of FG emphasizes the expanding role of endoscopic surgeons in multidisciplinary orbital surgery and highlights FG as a versatile adjunct in challenging orbital pathology.
- 30 March 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (9)
In Response to In‐Office Steroid Injections for Idiopathic Subglottic Stenosis: A Systematic Review
- 30 March 2026
- Published by Wiley in The Laryngoscope
- Vol. 136 (9)
In Response to In‐Office Steroid Injections for Idiopathic Subglottic Stenosis: A Systematic Review
- Open Access
- 22 March 2026
- Published by Wiley in Eye & ENT Research
- Vol. 3 (1) , 37-40
Vocal Fold Paralysis Following Peroral Endoscopic Myotomy for Zenker's Diverticula: A Case Report
- 22 March 2026
- Published by Wiley in Eye & ENT Research
- Vol. 3 (1) , 37-40
Open AccessVocal Fold Paralysis Following Peroral Endoscopic Myotomy for Zenker's Diverticula: A Case Report
- Open Access
- 17 February 2026
- Published by SAGE Publications in Ear, Nose & Throat Journal
Iatrogenic Subglottic Stenosis in Mast Cell Activation Syndrome: A Sentinel Case and Narrative Review
Subglottic stenosis (SGS) may arise from both mechanical and inflammatory airway injury. Patients with mast cell activation syndrome (MCAS) are uniquely vulnerable, due to both direct effects of systemic inflammation and indirect effects of repeated intubation for anaphylaxis that can converge to cause life-threatening airway compromise. We describe a sentinel case of a 34-year-old female with MCAS and multiple prior intubations who presented with progressive dyspnea. Flexible laryngoscopy revealed grade III SGS. She underwent urgent endoscopic intervention, including balloon dilation, carbon dioxide (CO 2 ) laser radial incisions, and steroid injection. Airway patency was restored, and postoperative care focused on optimizing systemic mast cell control with cromolyn, fexofenadine, montelukast, and omalizumab. Literature review supports a mechanistic role for mast cell mediators in airway fibrosis and impaired wound healing, compounding the effects of mechanical trauma in MCAS. This sentinel case highlights clinically significant risk of SGS in patients with MCAS. By integrating case findings with mechanistic insights, this report underscores the urgent need for interdisciplinary awareness, proactive airway evaluation, and research into surveillance and prevention strategies in MCAS and related disorders. Level of Evidence: Level V/Case Report and Narrative Review.
- 17 February 2026
- Published by SAGE Publications in Ear, Nose & Throat Journal
Open AccessIatrogenic Subglottic Stenosis in Mast Cell Activation Syndrome: A Sentinel Case and Narrative Review
Subglottic stenosis (SGS) may arise from both mechanical and inflammatory airway injury. Patients with mast cell activation syndrome (MCAS) are uniquely vulnerable, due to both direct effects of systemic inflammation and indirect effects of repeated intubation for anaphylaxis that can converge to cause life-threatening airway compromise. We describe a sentinel case of a 34-year-old female with MCAS and multiple prior intubations who presented with progressive dyspnea. Flexible laryngoscopy revealed grade III SGS. She underwent urgent endoscopic intervention, including balloon dilation, carbon dioxide (CO 2 ) laser radial incisions, and steroid injection. Airway patency was restored, and postoperative care focused on optimizing systemic mast cell control with cromolyn, fexofenadine, montelukast, and omalizumab. Literature review supports a mechanistic role for mast cell mediators in airway fibrosis and impaired wound healing, compounding the effects of mechanical trauma in MCAS. This sentinel case highlights clinically significant risk of SGS in patients with MCAS. By integrating case findings with mechanistic insights, this report underscores the urgent need for interdisciplinary awareness, proactive airway evaluation, and research into surveillance and prevention strategies in MCAS and related disorders. Level of Evidence: Level V/Case Report and Narrative Review.
- 6 December 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (5) , 2018-2025
In‐Office Steroid Injections for Idiopathic Subglottic Stenosis: A Systematic Review
Objectives: To critically evaluate clinical and voice‐related outcomes of in‐office serial intralesional steroid injection (SILSI) in adults diagnosed with idiopathic subglottic stenosis (iSGS). Data Sources: MEDLINE, Embase, CINAHL Ultimate, CENTRAL, ClinicalTrials.gov . Review Methods: A systematic search of databases was conducted from inception through April 5, 2025. Studies eligible for inclusion must have reported on adult SILSI recipients undergoing management of iSGS. Articles were independently screened and reviewed by two authors for treatment variables including steroid protocol, clinical outcomes, respiratory function, vocal outcomes, and complications. Results: Of 383 studies identified, 14 met inclusion criteria ( n = 371). Triamcinolone was the most commonly used agent in 10 studies. Steroid dosage, number of treatment sessions, and injection interval varied widely across studies. Improvements in surgery‐free interval, peak expiratory flow, dyspnea index, degree of stenosis, and voice‐related outcomes were observed in several studies. No major complications were reported in the included studies. Conclusion: Current evidence suggests SILSI represents a promising adjunctive therapy in the treatment of iSGS, with improvement noted across several measures. However, significant variability in steroid treatment regimens and inconsistent reporting of outcomes complicate interpretations of efficacy.
- 6 December 2025
- Published by Wiley in The Laryngoscope
- Vol. 136 (5) , 2018-2025
In‐Office Steroid Injections for Idiopathic Subglottic Stenosis: A Systematic Review
Objectives: To critically evaluate clinical and voice‐related outcomes of in‐office serial intralesional steroid injection (SILSI) in adults diagnosed with idiopathic subglottic stenosis (iSGS). Data Sources: MEDLINE, Embase, CINAHL Ultimate, CENTRAL, ClinicalTrials.gov . Review Methods: A systematic search of databases was conducted from inception through April 5, 2025. Studies eligible for inclusion must have reported on adult SILSI recipients undergoing management of iSGS. Articles were independently screened and reviewed by two authors for treatment variables including steroid protocol, clinical outcomes, respiratory function, vocal outcomes, and complications. Results: Of 383 studies identified, 14 met inclusion criteria ( n = 371). Triamcinolone was the most commonly used agent in 10 studies. Steroid dosage, number of treatment sessions, and injection interval varied widely across studies. Improvements in surgery‐free interval, peak expiratory flow, dyspnea index, degree of stenosis, and voice‐related outcomes were observed in several studies. No major complications were reported in the included studies. Conclusion: Current evidence suggests SILSI represents a promising adjunctive therapy in the treatment of iSGS, with improvement noted across several measures. However, significant variability in steroid treatment regimens and inconsistent reporting of outcomes complicate interpretations of efficacy.
- Open Access
- 1 September 2025
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (9)
Genomic profiling guided therapy for synchronous SCC and CLL of the parotid gland: a rare case report
Synchronous squamous cell carcinoma (SCC) and chronic lymphocytic leukemia (CLL) in the parotid gland is rare, with limited evidence on personalized treatment. We report a 75-year-old male with prior cutaneous SCC who presented with a hypermetabolic parotid mass and cervical lymphadenopathy; fine needle aspiration confirmed SCC. Surgery revealed poorly differentiated SCC and CLL in multiple lymph nodes. He underwent radiotherapy but developed regional SCC relapse without systemic CLL symptoms. Recurrence in the ear required extensive surgical resection and reconstruction. Genetic profiling showed high tumor mutational burden (>50 mutations/Mb) and mutations in ARID1B, CDKN2A, MSH2, PMS2, and TP53. He received six cycles of cemiplimab followed by cetuximab-based targeted therapy, based on rising circulating DNA levels. This case emphasizes the value of genetic profiling and tools like TMB, FISH, and immunohistochemistry for risk stratification and personalized treatment in managing advanced or complex parotid malignancies, including synchronous SCC and CLL, to optimize patient outcomes.
- 1 September 2025
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2025 (9)
Open AccessGenomic profiling guided therapy for synchronous SCC and CLL of the parotid gland: a rare case report
Synchronous squamous cell carcinoma (SCC) and chronic lymphocytic leukemia (CLL) in the parotid gland is rare, with limited evidence on personalized treatment. We report a 75-year-old male with prior cutaneous SCC who presented with a hypermetabolic parotid mass and cervical lymphadenopathy; fine needle aspiration confirmed SCC. Surgery revealed poorly differentiated SCC and CLL in multiple lymph nodes. He underwent radiotherapy but developed regional SCC relapse without systemic CLL symptoms. Recurrence in the ear required extensive surgical resection and reconstruction. Genetic profiling showed high tumor mutational burden (>50 mutations/Mb) and mutations in ARID1B, CDKN2A, MSH2, PMS2, and TP53. He received six cycles of cemiplimab followed by cetuximab-based targeted therapy, based on rising circulating DNA levels. This case emphasizes the value of genetic profiling and tools like TMB, FISH, and immunohistochemistry for risk stratification and personalized treatment in managing advanced or complex parotid malignancies, including synchronous SCC and CLL, to optimize patient outcomes.
- 12 July 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (10) , 3951-3956
Individualized Surgical Management for Thyroglossal Duct Cyst‐Papillary Thyroid Carcinoma: A Case Series
Objectives: Thyroglossal duct cyst (TGDC) associated carcinoma is rare, accounting for less than 2% of TGDC cases. The majority of cases are classified as papillary thyroid carcinoma (PTC). Standard treatment for TGDC‐PTC involves a Sistrunk procedure and prophylactic total thyroidectomy (TT). However, the necessity of these extensive surgical interventions remains debated. This report aims to explore whether individualized surgical approaches may reduce morbidity while maintaining favorable oncological outcomes.Methods: Retrospective case series of three patients with TGDC‐PTC.Results: The age range at presentation for our patients with TGDC‐PTC was 26 to 50. Case 1 involved a 38‐year‐old patient with a cystic mass near the hyoid bone and submental lymphadenopathy who underwent cyst excision with level Ia lymph node clearance. Case 2 is of a 50‐year‐old patient with a history of TGDC‐PTC who presented with a recurrent neck mass 9 years after the initial surgery and underwent a revision Sistrunk procedure. Case 3 presents a 26‐year‐old patient with a large TGDC and a benign thyroid nodule who underwent a Sistrunk procedure. All three patients had PTC confirmed by final pathology. All had no evidence of recurrent disease at follow‐up evaluations ranging from 1 to 12 years.Conclusion: This case series demonstrates the feasibility and safety of individualized surgical management for TGDC‐PTC. Risk stratification allowed for tailored interventions and avoided overly aggressive approaches. Further studies are needed to establish definitive guidelines for managing TGDC‐PTC, particularly in low‐risk patients.Level of Evidence: 4.
- 12 July 2025
- Published by Wiley in The Laryngoscope
- Vol. 135 (10) , 3951-3956
Individualized Surgical Management for Thyroglossal Duct Cyst‐Papillary Thyroid Carcinoma: A Case Series
Objectives: Thyroglossal duct cyst (TGDC) associated carcinoma is rare, accounting for less than 2% of TGDC cases. The majority of cases are classified as papillary thyroid carcinoma (PTC). Standard treatment for TGDC‐PTC involves a Sistrunk procedure and prophylactic total thyroidectomy (TT). However, the necessity of these extensive surgical interventions remains debated. This report aims to explore whether individualized surgical approaches may reduce morbidity while maintaining favorable oncological outcomes.Methods: Retrospective case series of three patients with TGDC‐PTC.Results: The age range at presentation for our patients with TGDC‐PTC was 26 to 50. Case 1 involved a 38‐year‐old patient with a cystic mass near the hyoid bone and submental lymphadenopathy who underwent cyst excision with level Ia lymph node clearance. Case 2 is of a 50‐year‐old patient with a history of TGDC‐PTC who presented with a recurrent neck mass 9 years after the initial surgery and underwent a revision Sistrunk procedure. Case 3 presents a 26‐year‐old patient with a large TGDC and a benign thyroid nodule who underwent a Sistrunk procedure. All three patients had PTC confirmed by final pathology. All had no evidence of recurrent disease at follow‐up evaluations ranging from 1 to 12 years.Conclusion: This case series demonstrates the feasibility and safety of individualized surgical management for TGDC‐PTC. Risk stratification allowed for tailored interventions and avoided overly aggressive approaches. Further studies are needed to establish definitive guidelines for managing TGDC‐PTC, particularly in low‐risk patients.Level of Evidence: 4.